Skip to content
Screener

Pacific Biosciences of California PACB EPS (Basic)

EPS (Basic) at other companies

Illumina logo
IlluminaILMN
$1.37-8.1%
Quanterix Corporation logo
Quanterix CorporationQTRX
-$1.04-35.1%
Revvity logo
RevvityRVTY
$0.36+2.9%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$0.71-7.6%
Agilent Technologies logo
Agilent TechnologiesA
$1.20+60.0%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$0.270.0%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$361.85M-12.6%
Enterprise value$361.04M-12.0%
P/S2.3×-0.4×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands, except per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Unrealized loss on investments(356)(114)(960)(155)
Comprehensive loss$(45,097)$(42,044)$(53,976)$(468,160)
Net loss per share:
Basic$(0.14)$(0.14)$(0.17)$(1.57)
Diluted$(0.14)$(0.14)$(0.17)$(1.57)
Weighted average shares outstanding used in calculating net loss per share:
Basic310,655300,162308,250298,519
Diluted310,655300,162308,250298,519

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's EPS (basic)?
Pacific Biosciences of California (PACB) reported EPS (basic) of -$0.14 in Q2 2026.
How has Pacific Biosciences of California's EPS (basic) changed year-over-year?
Pacific Biosciences of California's EPS (basic) decreased by 0.0% year-over-year, from -$0.14 to -$0.14.
What is the long-term trend for Pacific Biosciences of California's EPS (basic)?
Over 4 years (2021 to 2025), Pacific Biosciences of California's EPS (basic) has grown at a 19.2% compound annual growth rate (CAGR), from -$0.91 to -$1.84.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Pacific Biosciences of California's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude